S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

This study is currently recruiting participants.
Verified April 2014 by Southwest Oncology Group
Sponsor:
Collaborators:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT01668719
First received: August 16, 2012
Last updated: April 22, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)